glp 1 drugs novo nordisk asks FDA to prevent compounders from making GLP-1 knockoffs Novo Nordisk, Hims & Hers

Gastrointestinal Tolerability Over Time GI symptomsespecially nausea, vomiting, and constipationare among the most common complaints in GLP1 therapy

GLP-1 analogues possess anti-catabolic activity, as demonstrated by reduced MMP-3 and MMP-13 , ADAMTS4 , ADAMTS5 mRNA expression in TNF-stimulated human chondrocytes that was correlated with increased aggrecan and type II collagen protein levels [42,43]

3 Cardiovascular and renal disease models Preclinical models of atherosclerosis, hypertension, heart failure, and chronic kidney disease (CKD) enable scientists to determine how GLP-1R agonists influence vascular health

People with treatment-resistant hypertension, especially those with co-existing diabetes, obesity, heart failure (HF), or chronic kidney disease (CKD) may particularly benefit from SGLT2-i and GLP-1RA

Allen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, Kalynchuk LE

Researchers may combine Retatrutide studies with myostatin inhibitors like ACE-031 or growth hormone secretagogues like Ipamorelin to investigate strategies for muscle preservation during aggressive fat loss